

# Cutaneous Malignancies of the Nasal Pyramid: A 36-Case Retrospective Study of Reconstructive Outcomes at the University Hospital Center of Tangier, Morocco.

## ABSTRACT

**Background:** Cutaneous malignancies of the nasal pyramid represent a significant public health burden in sun-exposed populations. Despite their frequency, management remains challenging due to the complex three-dimensional anatomy and aesthetic importance of the nasal subunits. This study describes the epidemiological, clinicopathological, and therapeutic profiles of nasal pyramid tumors in a Moroccan cohort, with emphasis on reconstructive strategies.

**Methods:** A retrospective, descriptive, and analytical study was conducted over 24 months (October 2020–October 2022) at the Department of Plastic, Reconstructive and Aesthetic Surgery, Kortobi Hospital, Tangier. Thirty-six consecutive patients with histologically confirmed benign or malignant nasal pyramid tumors were included. Data were collected from medical records using a standardized extraction form and analyzed with Microsoft Excel 2019.

**Results:** The mean age was 68 years (range: 38–88), with male predominance (67%, sex ratio M/F = 2). Most patients (83%) were from rural areas, and 80% had significant occupational sun exposure. The mean diagnostic delay was 36 months. Basal cell carcinoma (BCC) accounted for 72% of cases and squamous cell carcinoma (SCC) for 28%. The lateral nasal wall was most frequently involved (50%). Surgical excision with 5–10 mm margins was performed in all patients. Reconstruction was immediate in 72% of cases, employing skin grafts (33%), local/regional flaps (33%), directed healing (17%), or direct closure (17%). No adjuvant radiotherapy or chemotherapy was required. At follow-up, no recurrences were observed, and aesthetic outcomes were acceptable in the majority, with flaps yielding superior results.

**Conclusion:** Nasal pyramid tumors in this North African cohort present with advanced disease due to diagnostic delays. Surgical excision with appropriate margins remains the cornerstone of treatment. Immediate reconstruction offers satisfactory oncological and aesthetic outcomes when tailored to defect location and size according to aesthetic subunit principles.

**Keywords:** nasal pyramid tumors; basal cell carcinoma; squamous cell carcinoma; nasal reconstruction; local flaps; skin grafts; Morocco; sun exposure

## I. INTRODUCTION

Cutaneous malignancies represent the most common human cancers in adults, accounting for approximately 90% of all skin cancers, with incidence increasing steadily due to population aging and behavioral risk factors, particularly chronic ultraviolet (UV) exposure [1]. The nasal pyramid, as a central and prominent facial structure, is disproportionately affected due to its continuous photodamage exposure and limited natural protection [2]. Surgical management of nasal tumors presents unique challenges: the nose serves critical aesthetic, respiratory, and social functions, and

40 its complex three-dimensional architecture—comprising skin, cartilage, bone, and mucosal lining—  
41 demands meticulous reconstructive planning [3].

42 The aesthetic subunit principle, originally described by Burget and Menick, has revolutionized nasal  
43 reconstruction by emphasizing the replacement of entire subunits (dorsum, tip, alae, sidewalls,  
44 columella) rather than patching defects, thereby optimizing camouflage and contour [4]. However, in  
45 oncological settings, strict adherence to subunit principles may be compromised by the need for  
46 adequate oncological margins, particularly in advanced or infiltrative tumors [5].

47 In Morocco and broader North Africa, cutaneous malignancies constitute a major public health  
48 concern, characterized by delayed diagnosis, limited access to specialized care, and frequent  
49 presentation with locally advanced disease [6]. The present study aims to describe the  
50 epidemiological, anatomopathological, clinical, and therapeutic profiles of nasal pyramid tumors  
51 managed at a tertiary plastic surgery center in Tangier, and to evaluate reconstructive outcomes  
52 using various surgical techniques.

## 53 **II. MATERIALS AND METHODS**

### 54 **1. Study Design and Setting**

55 This was a retrospective, descriptive, and analytical study conducted at the Department of Plastic,  
56 Reconstructive, Aesthetic and Burn Surgery, Kortobi Hospital, Tangier, Morocco. The study period  
57 spanned 24 months from October 2020 to October 2022.

### 58 **2. Participants**

59 Inclusion criteria comprised all male and female patients of any age with histologically confirmed  
60 benign or malignant tumors affecting the nasal pyramid and/or adjacent border zones. Exclusion  
61 criteria included:

- 62 • tumors of other facial locations;
- 63 • vascular cutaneous tumors (hemangiomas, angiomas);
- 64 • neurocutaneous syndromes (neurofibromatosis, tuberous sclerosis);
- 65 • viral-induced lesions;
- 66 • incomplete medical records.

### 67 **3. Data Collection**

68 A standardized data extraction form was developed based on literature review to capture:  
69 epidemiological variables (age, sex, profession, phototype, risk factors); clinical data (general  
70 examination, local and regional findings, lymph node status); paraclinical investigations  
71 (histopathology, imaging); therapeutic details (surgical margins, reconstruction method, anesthesia);  
72 and evolutionary outcomes (complications, recurrence, aesthetic and functional results). Data were  
73 retrieved from archived medical records and operative reports.

### 74 **4. Statistical Analysis**

75 Data were organized in Microsoft Excel 2019 and expressed as frequencies, percentages, or means  $\pm$   
76 standard deviation where appropriate.


### 77 **5. Ethical Considerations**

78 Data collection was performed anonymously. Patient consent for photographic documentation was  
79 obtained. The study was conducted without conflicts of interest and in accordance with the  
80 Declaration of Helsinki principles.


81 **III. RESULTS**

82 **1. Epidemiological Characteristics**

83 Thirty-six patients were included, with a mean case volume of 18 per year. The mean age at diagnosis  
84 was 68 years (range: 38–88 years), with 50% of patients concentrated in the 60–79 year age group. A  
85 marked male predominance was observed (67%, n=24; female 33%, n=12), yielding a male-to-female  
86 sex ratio of 2:1.




87  
88 **Figure 1:** Patient Sex Distribution



90  
91 **Figure 2:** Age Group Concentration

92 The majority of patients (83%, n=30) originated from rural areas of northern Morocco, while 17%  
93 (n=6) were urban residents. Occupational distribution revealed 60% were agricultural workers, 25%  
94 were housewives (the majority having performed outdoor work), and 15% held other occupations  
95 (manual laborers, military retirees).




96

97 **Figure 3:** Geographic Origin

98 **2. Risk Factors and Comorbidities**

99 According to Fitzpatrick classification, phototype III predominated (56%, n=20), followed by  
 100 phototype IV (33%, n=12) and phototype V (11%, n=4). All patients reported childhood and  
 101 adolescent sun exposure without adequate protection; 80% had significant occupational sun  
 102 exposure. Smoking was documented in 17% (n=6).



103

104 **Figure 4:** Phototype Distribution

105 Precancerous lesions were identified in 16% of patients: actinic keratosis (11%, n=4) and melanocytic  
 106 nevi (5%, n=2). No cases of xerodermapigmentosum, unstable scarring, or albinism were recorded.  
 107 Associated comorbidities included hypertension (33%, n=12), diabetes mellitus (22%, n=8), and one  
 108 case of post-thyroidectomy status.

109

110 **Table 1:** Precancerous Lesions, Notable Exclusions, and Associated Comorbidities

Variable	Findings
Precancerous Lesions	Identified in 16% of patients total: <ul style="list-style-type: none"><li>• Actinic keratosis: 11% (<math>n=4</math>)</li><li>• Melanocytic nevi: 5% (<math>n=2</math>)</li></ul>
Notable Exclusions	No cases of xerodermapigmentosum, unstable scarring, or albinism recorded
Associated Comorbidities	<ul style="list-style-type: none"><li>• Hypertension: 33% (<math>n=12</math>)</li><li>• Diabetes mellitus: 22% (<math>n=8</math>)</li><li>• Post-thyroidectomy status: 1 case</li></ul>

111

### 112 3. Clinical Presentation

113 The mean diagnostic delay—from lesion onset to consultation—was 36 months (range: 12–60  
114 months). Presenting symptoms included: chronic nodular lesions (56%); inflammatory signs (28%);  
115 painful lesions (28%); local superinfection with purulent discharge (22%); bleeding on contact (11%);  
116 and necrosis (11%). Notably, several patients reported prior use of traditional herbal remedies or  
117 self-mutilation, contributing to diagnostic delay and local aggravation.



118

119 **Figure 5:** Ulcerobudding appearance in a patient from our series.



120

121 **Figure 6:**Ulcerative appearance in a patient from our series.




122

123 **Figure 7:**Budding appearance with central necrosis in a patient from our series.

124

125




126

127 **Figure 8:** Clinical Presentation and Symptoms

128


129 Tumor distribution by aesthetic subunit was: lateral nasal wall 50% (n=18), dorsum 22% (n=8), nasal  
 130 tip 11.5% (n=4), nasal root 5% (n=2), and extended/multifocal involvement 11.5% (n=4). Tumor size  
 131 ranged from 10 mm to 50 mm; 33% were  $\leq 2$  cm (T1), 55% were 2–5 cm (T2), and 11% involved deep  
 132 structures (T4). No patient presented with regional lymphadenopathy or distant metastasis (NOM0 in  
 133 all cases).



134

135 **Figure 9:** Anatomical Distribution by Aesthetic Subunit

136 Macroscopic appearance was predominantly budding (39%), ulcerobudding (33%), ulcerative (6%),  
 137 infiltrative (11%), or necrotic (11%). No patient exhibited nasal obstruction.



138

139 **Figure 10:** Macroscopic Tumor Appearance

140

141

142

143

144

145

146

147 **Table 2:** Clinical Presentation and Tumor Characteristics


Variable	Findings
Mean diagnostic delay	36 months (range: 12–60 months)
Presentingsymptoms	<ul style="list-style-type: none"> <li>• Chronic nodular lesions: 56%</li> <li>• Inflammatory signs: 28%</li> <li>• Painful lesions: 28%</li> <li>• Local superinfection with purulent discharge: 22%</li> <li>• Bleeding on contact: 11%</li> <li>• Necrosis: 11%</li> </ul>
Contributingfactors to delay	Prior use of traditional herbal remedies or self-mutilation reported in several patients
Tumor distribution by nasal aesthetic subunit	<ul style="list-style-type: none"> <li>• Lateral nasal wall: 50% (<math>n=18</math>)</li> <li>• Dorsum: 22% (<math>n=8</math>)</li> <li>• Nasal tip: 11.5% (<math>n=4</math>)</li> <li>• Nasal root: 5% (<math>n=2</math>)</li> <li>• Extended/multifocal involvement: 11.5% (<math>n=4</math>)</li> </ul>
Tumor size	10–50 mm
Tumorstaging	<ul style="list-style-type: none"> <li>• T1 (<math>\leq 2</math> cm): 33%</li> <li>• T2 (2–5 cm): 55%</li> <li>• T4 (deep structure involvement): 11%</li> </ul>

Regional/distant spread	No regional lymphadenopathy or distant metastasis (NOMO in all cases)
Macroscopic appearance	<ul style="list-style-type: none"> <li>• Budding: 39%</li> <li>• Ulcerobudding: 33%</li> <li>• Ulcerative: 6%</li> </ul>

148

149 **4. Histopathological Findings**

150 Histological confirmation was obtained by preoperative biopsy in 44% (n=16) and by excisional  
 151 biopsy in 56% (n=20). BCC was the predominant type (72%, n=26), followed by SCC (28%, n=10). No  
 152 melanomas or benign tumors were encountered.



153

154 **Figure 11:** Histological Tumor Type Distribution

155 Among BCCs, the nodular subtype predominated (78%), with infiltrative subtype in 22%. No  
 156 sclerodermiform or superficial subtypes were identified. For SCCs: 16% were non-infiltrating (well-  
 157 differentiated 11%, moderately differentiated 5%) and 12% were infiltrating (all moderately  
 158 differentiated). No perineural invasion or vascular emboli were detected.

159 **Table 3:** Histopathological Findings

Variable	Findings
Mode of histological confirmation	<ul style="list-style-type: none"> <li>• Preoperative biopsy: 44% (n=16)</li> <li>• Excisional biopsy: 56% (n=20)</li> </ul>
Histological tumor types	<ul style="list-style-type: none"> <li>• Basal cell carcinoma (BCC): 72% (n=26)</li> <li>• Squamous cell carcinoma (SCC): 28% (n=10)</li> <li>• Melanoma: 0%</li> <li>• Benign tumors: 0%</li> </ul>
BCC subtypes	<ul style="list-style-type: none"> <li>• Nodular subtype: 78%</li> <li>• Infiltrative subtype: 22%</li> <li>• Sclerodermiform subtype: none</li> <li>• Superficial subtype: none</li> </ul>
SCC characteristics	<ul style="list-style-type: none"> <li>• Non-infiltrating SCC: 16%               <ul style="list-style-type: none"> <li>– Well-differentiated: 11%</li> <li>– Moderately differentiated: 5%</li> </ul> </li> </ul>

	• Infiltrating SCC: 12% – All moderately differentiated
Perineural invasion / vascularemboli	None detected

160

### 161 5. Surgical Management

162 All patients underwent surgical excision. Local anesthesia was used for 12 patients (33%) with small  
 163 lesions (<1 cm), while general anesthesia was required for 24 patients (67%) with larger or complex  
 164 defects. Preoperative marking of excision margins was systematically performed. Lateral and deep  
 165 margins ranged from 5–10 mm according to histological type and tumor size. Deep resection  
 166 involved cartilage in 16% (n=6), mucosa in 11% (n=4), and septum in 5% (n=2); no bony resection was  
 167 required. All excision margins were histologically clear.



168

169 **Figure 12:** The incision markings in a patient from our series.

170

171 **Table 4:** Surgical Management and Excision Characteristics

Variable	Findings
Surgical treatment	All patients underwent surgical excision
Type of anesthesia	<ul style="list-style-type: none"> <li>• Local anesthesia: 33% (n=12) for small lesions (&lt;1 cm)</li> <li>• General anesthesia: 67% (n=24) for larger or complex defects</li> </ul>
Preoperative planning	Systematic preoperative marking of excision margins performed in all cases
Excision margins	Lateral and deep margins ranged from 5–10 mm depending on histological type and tumor size
Deep resection involvement	<ul style="list-style-type: none"> <li>• Cartilage: 16% (n=6)</li> <li>• Mucosa: 11% (n=4)</li> <li>• Septum: 5% (n=2)</li> <li>• Bone: none</li> </ul>
Histological margin status	All excision margins were histologically clear

172

173



174

175 **Figure 13:** The extent and depth of the surgical excision in a female patient from our series.

176

177 No patient required lymph node dissection. Reconstruction was immediate in 72% (n=26) and  
 178 delayed (pending histological confirmation) in 28% (n=10). Reconstructive methods included (table  
 179 5):

180

181

182


183

184

185 **Table 5:** Reconstructive Techniques

Reconstructive Technique	n (%)	Indications
Direct suture	6 (17%)	Small defects (<1 cm), dorsum/lateral wall
Directed healing	6 (17%)	Tip/dorsum defects, patient refusal of reconstruction
Full-thickness skin graft	12 (33%)	Dorsum, tip, root defects; supraclavicular/retroauricular donor sites
Local/regional flaps	12 (33%)	Various subunits; glabellar, forehead, nasolabial, Rintala advancement
Cartilage graft	6 (17%)	Structural support (conchal, septal, costal cartilage)

186



187  
188 **Figure 14:** Reconstructive Techniques Distribution  
189



190 **Figure 15:** **A:** Post-tumor excision tissue defect / **B:** Outcome after directed healing (second intention  
191 healing) in a female patient who refused reconstruction.  
192




193  
194  
195 **Figure 16:** **A:** Resection of a tumor located at the root of the nose / **B:** Reconstruction using a full-  
196 thickness skin graft harvested from the supraclavicular fossa in a patient from our series.  
197

198

199

200 The bilobed flap, nasolabial flap, forehead flap, and Rintala advancement flap were employed  
201 according to defect location and size. No free flaps were required.



202

203 **Figure 17:**A: Resection of a tumor located on the dorsum / B: Reconstruction using a glabellar flap  
204 combined with a full-thickness skin graft harvested from the antitragus.



205

206 **Figure 18:** Total excision of the nasal pyramid followed by skin layer reconstruction using a forehead  
207 flap.

208



209

210 **Figure 19:A:** Resection of a tumor located on the dorsum / **B:** Reconstruction using a Rintala  
211 advancement flap.

## 212 6. Outcomes and Follow-up

213 No adjuvant radiotherapy or chemotherapy was administered. Immediate postoperative course was  
214 uncomplicated in most patients; one hematoma resolved after drainage. No cases of flap necrosis,  
215 dehiscence, or graft loss were recorded.

216 At available follow-up, no local recurrences or new primary lesions were detected. Aesthetic results  
217 were judged acceptable in the majority of cases. Functional outcomes (nasal patency, symmetry)  
218 were satisfactory. Flap reconstructions yielded superior aesthetic results compared to skin grafts or  
219 directed healing, consistent with established principles of like-tissue replacement [7].

220 Surveillance protocol included: immediate postoperative monitoring to day 15; quarterly clinical  
221 examination for 2 years; and annual examination thereafter for 5 years to detect recurrence or new  
222 primaries.

223 **Table 6:** Postoperative Complications & Safety Outcomes

Postoperative Outcome	Percentage	Clinical Notes / Resolution
Uncomplicated Course	97.2%	Majority of the cohort
Hematoma	2.8%	Resolved completely after drainage
Flap Necrosis	0.0%	None recorded
Graft Loss	0.0%	None recorded
Wound Dehiscence	0.0%	None recorded

224



225

226 **Figure 20:** Aesthetic result 6 months after reconstruction using a glabellar flap.

227



228

229 **Figure 21:** Aesthetic result of a nasal defect left to heal by directed healing (second intention  
230 healing).

231



232

233 **Figure 22:** Aesthetic result 1 year after reconstruction using a full-thickness skin graft.

## 234 **IV. DISCUSSION**

### 235 **1. Epidemiological Context**

236 The present cohort demonstrates characteristics typical of cutaneous malignancies in North African  
237 populations: advanced age at presentation (mean 68 years), male predominance, rural residence,  
238 and significant occupational sun exposure [8]. The male-to-female ratio of 2:1 exceeds some Western  
239 series but aligns with regional reports, likely reflecting greater outdoor occupational exposure among  
240 men in agrarian economies and protective clothing practices among women [9]. The predominance  
241 of phototypes III–IV (89%) reflects the Mediterranean/North African phenotype, which carries  
242 intermediate skin cancer risk compared to fair-skinned populations [10].

243 The 36-month mean diagnostic delay is concerning and exceeds intervals reported in European series  
244 (12–15 months) [11]. This delay stems from multiple factors: geographical isolation, limited  
245 healthcare access, low socioeconomic status, cultural beliefs leading to traditional remedy use, and  
246 the painless, indolent nature of BCCs. Public health interventions targeting early detection in rural  
247 communities are urgently needed.

## 248 2. Histopathological Profile

249 The BCC: SCC ratio of 2.6:1 (72%:28%) is consistent with global patterns and regional Moroccan data  
250 [12]. The predominance of nodular BCC (78%) and absence of sclerodermiform variants may reflect  
251 selection bias toward exophytic, clinically apparent lesions in this retrospective series. The infiltrative  
252 SCC proportion (12%) warrants attention given its association with aggressive behavior and higher  
253 metastatic potential [13]. Notably, no melanomas were encountered, consistent with the established  
254 predilection for acral (plantar) locations in darker-skinned populations [14].

## 255 3. Oncological Management

256 Surgical excision with histologically clear margins remains the gold standard for curative treatment of  
257 non-melanoma skin cancer [15]. Our margin policy (5–10 mm) aligns with international guidelines: 3–  
258 4 mm for low-risk BCC, extending to 10–15 mm for high-risk or recurrent lesions; and 4–6 mm for SCC  
259 <2 cm, with wider margins for larger or high-risk tumors [16]. The 100% rate of clear margins in this  
260 series likely reflects the advanced stage permitting macroscopic margin assessment, though it may  
261 also indicate adequate surgical technique. Mohs micrographic surgery, which offers superior margin  
262 control and tissue preservation, was unavailable at our institution but should be considered for high-  
263 risk facial tumors when feasible [17].

264 The absence of lymph node dissection in all patients is appropriate given N0 status; prophylactic  
265 dissection is not indicated in clinically negative necks for non-melanoma skin cancer [18].

## 266 4. Reconstructive Considerations

267 Nasal reconstruction demands restoration of three-dimensional form, function, and aesthetic subunit  
268 integrity [19]. Our reconstructive algorithm prioritized simplicity and reliability: direct closure for  
269 small defects, skin grafts for superficial dorsal/root defects, and local flaps for larger or complex  
270 defects involving multiple subunits.

271 The 33% flap utilization rate is comparable to published series [20]. Local flaps (bilobed, nasolabial,  
272 glabellar, forehead) provided superior color, texture, and thickness match compared to grafts,  
273 particularly for the sebaceous nasal tip and alar regions [21]. The forehead flap, though requiring  
274 staged pedicle division, remains the workhorse for large nasal defects, offering robust vascularity  
275 from the supratrochlear artery and excellent aesthetic outcomes [22].

276 Immediate reconstruction in 72% of cases did not compromise oncological safety, consistent with  
277 recent evidence that immediate flap reconstruction following standard excision does not increase  
278 recurrence risk [23]. Delayed reconstruction (28%) was reserved for cases requiring histological  
279 margin confirmation or complex multistage procedures.

## 280 5. Prevention and Public Health Implications

281 The heavy burden of advanced disease in this cohort underscores the need for comprehensive  
282 prevention strategies. Primary prevention should target sun protection education, particularly for  
283 outdoor workers; secondary prevention requires systematic screening of high-risk individuals and  
284 prompt referral of suspicious lesions; tertiary prevention focuses on functional rehabilitation and  
285 psychosocial reintegration [24]. The frequent use of traditional remedies observed in our patients  
286 highlights the importance of culturally sensitive health education.

## 287 6. Limitations

288 This study's retrospective design, single-center setting, and limited sample size (n=36) restrict  
289 generalizability. Follow-up duration was insufficient to definitively assess long-term recurrence rates,  
290 particularly for SCC where late metastasis may occur. The absence of standardized aesthetic scoring

291 precludes objective comparison with other series. Additionally, the lack of Mohs surgery availability  
292 may have influenced margin status and reconstruction complexity.

## 293 **V. CONCLUSION**

294 Nasal pyramid cutaneous tumors in this Moroccan cohort present with advanced stage disease due  
295 to substantial diagnostic delays, reflecting healthcare access disparities in rural populations. Basal cell  
296 carcinoma predominates, with the lateral nasal wall most commonly affected. Surgical excision with  
297 appropriate margins and tailored immediate reconstruction achieves satisfactory oncological and  
298 functional outcomes. Local and regional flaps provide superior aesthetic results compared to skin  
299 grafts or secondary intention healing. Enhanced public awareness, early detection programs, and  
300 improved access to specialized care are essential to reduce disease burden and optimize outcomes in  
301 similar resource-limited settings.

302

## 303 **REFERENCES**

- 304 [1] Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of  
305 nonmelanoma skin cancer. *Br J Dermatol.* 2012;166(5):1069-1080.
- 306 [2] Peris K, Fargnoli MC, Kaufmann R, et al. European consensus-based interdisciplinary guideline for  
307 diagnosis and treatment of basal cell carcinoma—update 2023. *Eur J Cancer.* 2023;192:113254.
- 308 [3] Burget GC, Menick FJ. The subunit principle in nasal reconstruction. *Plast Reconstr Surg.*  
309 1985;76(2):239-247.
- 310 [4] Menick FJ. Nasal reconstruction: forehead flap. *Plast Reconstr Surg.* 2004;113(4):100E-111E.
- 311 [5] Chaput B, Lauwers F, Lopez R, et al. L'anatomie chirurgicale du nez en six sous-unités esthétiques.  
312 *Ann Chir Plast Esthet.* 2013;58(2):132-145.
- 313 [6] Elhaouri M, et al. Les cancers de peau (À propos de 194 cas). Centre Hospitalier Universitaire  
314 Hassan II, Fès. Available at: <http://www.chu-fes.ma/les-cancers-de-peau-a-propos-de-194-cas/>
- 315 [7] Veija T, Koivunen V, Mäkelä L, et al. Immediate local flap versus skin graft reconstruction after  
316 standard excision of basal cell carcinoma of the nose. *JPRAS Open.* 2025;44:364-374.
- 317 [8] Ferreira FR, Costa Nascimento LF, Rotta O. Risk factors for non-melanoma skin cancer in Taubaté,  
318 São Paulo, Brazil: a case-control study. *Rev Assoc Med Bras.* 2011;57(4):424-430.
- 319 [9] Mernissi FZ, et al. Les tumeurs cutanées malignes (À propos de 115 cas). CHU Hassan II, Fès.
- 320 [10] Benslimane Z. Traitement chirurgical des tumeurs nasales: À propos de 15 cas. Thèse de  
321 Médecine, Université Mohammed V, Rabat; 2020.
- 322 [11] Compte D. Traitement des tumeurs malignes du revêtement cutané du nez. Thèse de Médecine,  
323 Université Claude Bernard Lyon I; 1988.
- 324 [12] Staub G, Revol M, May P, et al. Marges d'exérèse chirurgicale et taux de récurrence des carcinomes  
325 cutanés: Étude prospective de 844 cas. *Ann Chir Plast Esthet.* 2008;53(5):389-398.
- 326 [13] Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival  
327 rates in squamous cell carcinoma of the skin, ear, and lip. *J Am Acad Dermatol.* 1992;26(6):976-990.
- 328 [14] Bradford PT. Skin cancer in skin of color. *Dermatol Nurs.* 2009;21(4):170-178.

- 329 [15] Peris K, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment  
330 of basal cell carcinoma—update 2023. *Eur J Cancer*. 2023;192:113254.
- 331 [16] Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell  
332 carcinoma. *J Am Acad Dermatol*. 1992;27(2 Pt 1):241-248.
- 333 [17] Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously  
334 treated) basal cell carcinoma. *J Dermatol Surg Oncol*. 1989;15(4):424-431.
- 335 [18] Bessède JP, Vinh D, Khalifa N, et al. Métastases ganglionnaires des carcinomes épidermoïdes  
336 cutanés cervicofaciaux. *Rev Laryngol Otol Rhinol*. 2001;122:111-117.
- 337 [19] Burget GC, Menick FJ. Nasal support and lining: the marriage of beauty and blood supply.  
338 *Plast Reconstr Surg*. 1989;84(2):189-202.
- 339 [20] Kaya I, Uslu M, Apaydin F. Defect reconstruction of the nose after surgery for nonmelanoma skin  
340 cancer. *J Skin Cancer*. 2017;2017:320792.
- 341 [21] Park YJ, Kwon GH, Kim JO, et al. Reconstruction of nasal ala and tip following skin cancer  
342 resection. *Arch Craniofac Surg*. 2019;20(6):386-392.
- 343 [22] Rao J, Deora H. Surgical excision with forehead flap as single modality treatment for basal cell  
344 cancer of central face: single institutional experience of 50 cases. *J Skin Cancer*. 2014;2014:320792.
- 345 [23] Veija T, Koivunen V, Mäkelä L, et al. Immediate local flap versus skin graft reconstruction after  
346 standard excision of basal cell carcinoma of the nose. *JPRAS Open*. 2025;44:364-374.
- 347 [24] Bonerandi JJ, Monestier S. Carcinome épidermoïde (spinocellulaire) et ses précurseurs. *EMC*  
348 *Dermatologie*. 2011;98-625-A-10.